Module HEME-32 · Version 1.0
Hematopoietic Stem-Cell Transplantation: A Laboratory Timeline
Follow the laboratory questions that arise before collection, during conditioning and infusion, through engraftment, and during post-transplant monitoring after hematopoietic stem-cell transplantation (HSCT), connecting collection, product testing, engraftment, chimerism, disease monitoring, transfusion support, and complication workups within stated method limits.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
MLS/MLT students transitioning to bench practice and new bench technologists in hematology, cellular therapy, or transfusion services, with prior hematology, transfusion, molecular, and immunology fundamentals.
Learning objectives
- Identify pretransplant donor/recipient and baseline testing domains
- Explain collection/product counts, viability, sterility, labeling, and chain-of-identity concepts
- Interpret count recovery, chimerism, and disease-monitoring trends within method limitations
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
14 sources
1. Carreras E, et al., editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, 8th ed. Springer; 2024. Chapters on mobilization, engraftment, and graft failure.
Source note · professional society guidance
2. Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee ISCT-Europe & EBMT. FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration, Ninth Edition, Version 9.1, effective 2026-02-02.
Source note · accreditation standard
3. Dehn J, et al. Current HLA testing recommendations to support hematopoietic cell transplantation. Human Immunology. 2022;83:737-744.
Source note · professional society guidance
4. U.S. Food and Drug Administration. Testing Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P): Specific Requirements.
Source note · federal guidance
5. Schrezenmeier H, Korper S, Hochsmann B, Weinstock C. Transfusion Support. In: The EBMT Handbook, 8th ed. 2024, chapter 24.
Source note · professional society guidance
6. Clinical and Laboratory Standards Institute. H42-A2: Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline, 2nd ed., reaffirmed 2017.
Source note · consensus standard
7. Clinical and Laboratory Standards Institute. H43-A2: Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline, 2nd ed., reaffirmed 2017.
Source note · consensus standard
8. Tozzo P, Delicati A, Zambello R, Caenazzo L. Chimerism Monitoring Techniques after Hematopoietic Stem Cell Transplantation: An Overview of the Last 15 Years of Innovations. Diagnostics. 2021;11:621. doi:10.3390/diagnostics11040621.
Source note · peer-reviewed literature
9. Heuser M, et al. 2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753-2767.
Source note · professional society guidance
10. Centers for Medicare & Medicaid Services. 42 CFR Part 493, Laboratory Requirements. Current eCFR, Subpart K, especially SS493.1200, 493.1252, and 493.1253.
Source note · federal guidance
11. College of American Pathologists. Laboratory General Checklist, GEN.40490 Patient Identification (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
12. College of American Pathologists. All Common Checklist, COM.06200 Secondary Specimen Container Labeling (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
13. College of American Pathologists. Hematology, Coagulation, and Clinical Microscopy Checklist, HEM.36030 Bone Marrow Procedures (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
14. Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 2021;27(8):642-649.
Source note · professional society guidance